Last reviewed · How we verify
NCT02828904: RIVET-RCS
RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism
trial in Venous Thromboembolism in 124,000 participants. Completed in 31 January 2024.
15 January 2024
Quick facts
| Lead sponsor | Center for Epidemiology and Health Research, Germany |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 124,000 |
| Start date | 10 March 2022 |
| Primary completion | 15 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Germany |
Conditions studied
- Venous Thromboembolism — all drugs for Venous Thromboembolism →
Sponsor
Center for Epidemiology and Health Research, Germany — full company profile →
Who can join
Adults 15 to 49, female only, with Venous Thromboembolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The risk of venous thromboembolism (VTE) associated with the use of chlormadinone acetate (CMA) compared to the gold-standard progestin levonorgestrel (LNG) as component of combined oral contraceptives (COC) is currently unknown. The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended a pooled analysis of four prospective cohort studies carried out by the Berlin Center for Epidemiology and Health Research (ZEG Berlin) in order to clarify whether CMA-containing COCs carry a different VTE risk compared to LNG-containing COCs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02828904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Venous Thromboembolism
Currently open trials in the same condition.
- NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
- NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
- NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting
Other Center for Epidemiology and Health Research, Germany trials
Trials by the same sponsor.
- NCT06028555 — International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study · recruiting
- NCT05186779 — Maternal and Newborn Safety Profile of Progestogens in EARLY Pregnancy · terminated
- NCT04065464 — TRACY - Track My Cycle · completed
- NCT02494297 — DUS on the Prescribing Indications for CPA/EE in 5 European Countries · completed
- NCT01266421 — Visanne Post-approval Observational Study (VIPOS) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02828904 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Center for Epidemiology and Health Research, Germany
- Last refreshed: 5 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02828904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing